A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
Neonc Technologies, Inc.
ImmunityBio, Inc.
Incyte Corporation
Exelixis
Molecular Templates, Inc.
Fate Therapeutics
Clovis Oncology, Inc.
Incyte Corporation
MultiVir, Inc.